Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
21st Mar 20127:00 amPRNUnaudited Preliminary Results
19th Mar 20127:00 amPRNNotification of Preliminary Results
10th Feb 20127:00 amPRNSilence Therapeutics Announces Board Changes and New CEO
27th Jan 20124:40 pmRNSSecond Price Monitoring Extn
27th Jan 20124:35 pmRNSPrice Monitoring Extension
26th Jan 20127:00 amPRNTR-1: Notifications of Major Interest in Shares
23rd Jan 20127:00 amPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Jan 20127:00 amPRNSilence signs collaboration with miRagen Therapeutics
6th Jan 20127:00 amPRNResearch and Development Collaboration Update
30th Dec 20117:00 amPRNTotal Voting Rights
20th Dec 20114:40 pmRNSSecond Price Monitoring Extn
20th Dec 20114:35 pmRNSPrice Monitoring Extension
20th Dec 20117:00 amPRNAdditional Listing
12th Dec 20117:00 amPRNPositive Response by USPTO
9th Dec 20114:40 pmRNSSecond Price Monitoring Extn
9th Dec 20114:35 pmRNSPrice Monitoring Extension
7th Dec 20111:27 pmPRNPositive outcome from oral hearing at Patent Office
22nd Nov 20114:40 pmRNSSecond Price Monitoring Extn
22nd Nov 20114:35 pmRNSPrice Monitoring Extension
8th Nov 20117:00 amPRNSilence Therapeutics provides update
24th Oct 20117:00 amPRNCollaboration with Mirna Therapeutics
14th Oct 20117:00 amPRNGrant of options
3rd Oct 20117:00 amPRNDirectors’ share purchases
21st Sep 20117:00 amPRNAppointment of Chief Business Officer
21st Sep 20117:00 amPRNInterim Results for the Six Months Ended 30 June 2011
20th Sep 20117:00 amPRNAppointment of Chief Executive Officer
14th Sep 201110:32 amPRNNotice of Results
13th Sep 20114:40 pmRNSSecond Price Monitoring Extn
13th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20119:24 amPRNSilence & InteRNA Technologies collaboration
8th Sep 20114:40 pmRNSSecond Price Monitoring Extn
8th Sep 20114:35 pmRNSPrice Monitoring Extension
5th Sep 20114:40 pmRNSSecond Price Monitoring Extn
5th Sep 20114:35 pmRNSPrice Monitoring Extension
1st Sep 20114:40 pmRNSSecond Price Monitoring Extn
1st Sep 20114:35 pmRNSPrice Monitoring Extension
31st Aug 20114:40 pmRNSSecond Price Monitoring Extn
31st Aug 20114:35 pmRNSPrice Monitoring Extension
26th Aug 20114:40 pmRNSSecond Price Monitoring Extn
26th Aug 20114:35 pmRNSPrice Monitoring Extension
23rd Aug 20114:41 pmRNSSecond Price Monitoring Extn
23rd Aug 20114:35 pmRNSPrice Monitoring Extension
22nd Aug 20114:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20114:35 pmRNSPrice Monitoring Extension
18th Aug 20114:41 pmRNSSecond Price Monitoring Extn
18th Aug 20114:35 pmRNSPrice Monitoring Extension
12th Aug 20114:40 pmRNSSecond Price Monitoring Extn
12th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20114:40 pmRNSSecond Price Monitoring Extn
11th Aug 20114:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.